Chlorhexidine Sumatra Benzoin Filtration and HPLC Testing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The use of compendial-grade Sumatra benzoin BP in topical antibacterial coatings containing chlorhexidine poses challenges due to its particulate nature, requiring additional filtration steps that lead to solvent and active ingredient losses, and existing HPLC methods struggle to accurately test for chlorhexidine and its related substances due to interference from Sumatra benzoin BP.

Innovation Solution

A multi-step filtration process is implemented to produce a particulate-free stock solution of chlorhexidine diacetate in ethanolic Sumatra benzoin BP, and a method involving an acidic aqueous medium is used to strip Sumatra benzoin BP before HPLC testing, allowing for accurate determination of chlorhexidine and its related substances.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If compendial-grade Sumatra benzoin BP is used in topical antibacterial coatings, then regulatory compliance is improved, but additional filtration steps are required causing solvent and active ingredient losses

Engineering Contradiction:
Improveregulatory complianceVSAvoidsolvent and active ingredient losses
Core Design Contradiction:
ReliabilityVSLoss of substance

Solution Approach 1:

The patent applies preliminary action by performing the filtration of Sumatra benzoin BP before dissolving chlorhexidine diacetate in the ethanolic solution. This sequence ensures that particulate matter is removed from the benzoin solution prior to adding the active ingredient, thereby preventing clogging of filtration equipment during subsequent steps and minimizing losses of both solvent and active ingredient while maintaining regulatory compliance

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent uses an intermediary approach by introducing a multi-stage filtration system with progressively finer filters (e.g., 100 μm, 40 μm, and 1.2 μm filters) as intermediate steps between the crude Sumatra benzoin BP and the final topical coating product. This intermediary filtration process gradually removes particulates without subjecting the active ingredient to excessive stress, thereby reducing losses while achieving the required clarity and compliance

Inventive Principle:
Principle #24Intermediary (Mediator)

2Manufacturing precision

If multi-step filtration is implemented to remove particulates from Sumatra benzoin BP, then product clarity is improved, but process complexity and time increase

Engineering Contradiction:
Improveproduct clarityVSAvoidfiltration process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the filtration process into multiple discrete stages, each with a specific filter pore size (e.g., 100 μm for initial filtration, 40 μm for intermediate filtration, and 1.2 μm for final filtration). This segmented approach allows each filtration step to target specific particle size ranges, achieving superior product clarity while making the overall process more manageable and controllable despite the increased number of steps

Inventive Principle:
Principle #1Segmentation

3Ease of operation

If HPLC testing is performed directly on the topical coating containing Sumatra benzoin BP, then testing simplicity is maintained, but measurement accuracy of chlorhexidine and related substances deteriorates due to interference

Engineering Contradiction:
Improvetesting simplicityVSAvoidchlorhexidine and related substances determination accuracy
Core Design Contradiction:
Ease of operationVSMeasurement precision

Solution Approach 1:

The patent applies the taking out principle by extracting and removing Sumatra benzoin BP from the topical coating matrix before HPLC analysis. This is achieved through a liquid-liquid extraction process where the coating is dissolved and then partitioned between aqueous and organic phases, with the benzoin selectively retained in one phase while chlorhexidine diacetate and its related substances are extracted into the other phase suitable for HPLC injection. This separation eliminates interference from benzoin particles and ensures accurate measurement of the active ingredient

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses an intermediary extraction step as a mediator between the topical coating matrix and the HPLC analysis. By introducing this intermediate purification step, the complex matrix components (particularly Sumatra benzoin BP particulates) are separated from the analytes of interest (chlorhexidine diacetate and related substances), allowing the HPLC system to operate with simple, particulate-free samples while maintaining comprehensive analysis of all relevant components

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process ensures compliance with regulatory standards by maintaining the potency and purity of chlorhexidine while overcoming the limitations of using compendial-grade Sumatra benzoin BP, ensuring the finished product meets international regulatory specifications.

Implementation Method 1

involved the precipitation of Sumatra benzoin from a topical antibacterial coating

Methodology Applied
Scientific EffectPrecipitation: Precipitation

Data Source

PatentEP2166838B1Topical dental solution of chlorhexidine in sumatra benzoin BP/EP and methods of manufacturing and evaluating same
Publication Date: 2018.10.24 CHX TECH
  • EP2166838B1 patent drawingFigure 1
  • EP2166838B1 patent drawingFigure 2
  • EP2166838B1 patent drawingFigure 3a~3c

AI summary

A method of manufacturing a topical, antibacterial coating containing chlorhexidine, as the active anti-bacterial agent, in a matrix of the natural substance, specifically a compendial grade of Sumatra benzoin, so as to comply with existing specifications for the drug product under international regulatory standards by novel HPLC and colorimetric test methods.